- OralAlectinibAlecensaBetter CNS penetration than crizotinib
Mechanism of Action
- Anaplastic lymphoma kinase (ALK) is a novel receptor tyrosine kinase associated with ~60% of anaplastic large-cell lymphoma and ~5% of non-small cell lung cancer. Inhibition of these receptors interrupts downstream signalling pathways and suppresses cellular proliferation.
- ALK-positive locally advanced or metastatic non small cell lung cancer (NSCLC).
- Adverse Effects
- Visual phenomena
- Nausea / vomiting / diarrhoea
- LFT derangement